566 related articles for article (PubMed ID: 25432859)
1. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
3. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
5. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
6. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
Nagill R; Mahajan R; Sharma M; Kaur S
Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
[TBL] [Abstract][Full Text] [Related]
7. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis.
Kaur H; Thakur A; Kaur S
Parasite Immunol; 2015 Apr; 37(4):192-203. PubMed ID: 25615543
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
Joshi J; Malla N; Kaur S
Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
[TBL] [Abstract][Full Text] [Related]
10. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
11. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
12. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice.
Goyal DK; Keshav P; Kaur S
Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508
[TBL] [Abstract][Full Text] [Related]
13. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
Kaur J; Kaur T; Kaur S
Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
[TBL] [Abstract][Full Text] [Related]
14. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes.
Afrin F; Anam K; Ali N
J Parasitol; 2000 Aug; 86(4):730-5. PubMed ID: 10958448
[TBL] [Abstract][Full Text] [Related]
15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
16. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
Bhowmick S; Ravindran R; Ali N
BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
[TBL] [Abstract][Full Text] [Related]
17. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
19. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.
Sabur A; Bhowmick S; Chhajer R; Ejazi SA; Didwania N; Asad M; Bhattacharyya A; Sinha U; Ali N
Front Immunol; 2018; 9():18. PubMed ID: 29441060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
